
Nuvalent, Inc. — Investor Relations & Filings
Nuvalent, Inc. is a clinical-stage company developing precisely targeted therapies for patients with cancer. Leveraging deep expertise in chemistry and structure-based drug discovery, the company designs innovative small molecule kinase inhibitors. These therapies are engineered to overcome the limitations of existing treatments by addressing the dual challenges of drug resistance and kinase selectivity. Nuvalent is advancing a pipeline of novel drug candidates with parallel lead programs targeting ROS1-positive and ALK-positive non-small cell lung cancer (NSCLC). The company's portfolio includes NVL-655, an ALK-selective inhibitor that has received U.S. FDA Breakthrough Therapy Designation.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 10-Q - Nuvalent, Inc. (0001861560) (Filer) | 2026-05-07 | English | |
| 8-K - Nuvalent, Inc. (0001861560) (Filer) | 2026-05-07 | English | |
| ARS - Nuvalent, Inc. (0001861560) (Filer) | 2026-04-28 | English | |
| DEF 14A - Nuvalent, Inc. (0001861560) (Filer) | 2026-04-28 | English | |
| 8-K - Nuvalent, Inc. (0001861560) (Filer) | 2026-04-07 | English | |
| 4 - Nuvalent, Inc. (0001861560) (Issuer) | 2026-03-30 | English |
Browse filings by year
6 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 42789675 | 10-Q - Nuvalent, Inc. (0001861560) (Filer) | 2026-05-07 | English | ||
| 42789245 | 8-K - Nuvalent, Inc. (0001861560) (Filer) | 2026-05-07 | English | ||
| 38165707 | ARS - Nuvalent, Inc. (0001861560) (Filer) | 2026-04-28 | English | ||
| 38165685 | DEF 14A - Nuvalent, Inc. (0001861560) (Filer) | 2026-04-28 | English | ||
| 33699756 | 8-K - Nuvalent, Inc. (0001861560) (Filer) | 2026-04-07 | English | ||
| 33092910 | 4 - Nuvalent, Inc. (0001861560) (Issuer) | 2026-03-30 | English | ||
| 33035778 | 144 - Nuvalent, Inc. (0001861560) (Subject) | 2026-03-24 | English | ||
| 32900006 | 4 - NUVALENT, INC. (0001861560) (Filer) | 2026-03-02 | English | ||
| 32900007 | 4 - NUVALENT, INC. (0001861560) (Filer) | 2026-03-02 | English | ||
| 32900009 | 10-K - NUVALENT, INC. (0001861560) (Filer) | 2026-02-26 | English | ||
| 32900008 | 8-K - NUVALENT, INC. (0001861560) (Filer) | 2026-02-26 | English | ||
| 32108228 | SCHEDULE 13G/A Filing | 2026-02-12 | English | ||
| 32108227 | 4 Filing | 2026-02-02 | English | ||
| 13454945 | 4 | 2026-01-23 | English | ||
| 13454948 | Regulatory Filings 2026 | 2026-01-22 | English | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
ANHUI FENGYUAN PHARMACEUTICAL CO., LTD
Produces injections, solid dosage forms, APIs, and nutritio…
|
000153 | CN | Manufacturing |
|
Anhui Huangshan Capsule Co.,Ltd
Produces empty hard capsules, including gelatin and HPMC ve…
|
002817 | CN | Manufacturing |
|
Anhui Sunhere Pharmaceutical Excipients Co.,Ltd
Develops and manufactures pharmaceutical excipients for sol…
|
300452 | CN | Manufacturing |
|
Anika Therapeutics, Inc.
A global joint preservation company developing solutions fo…
|
ANIK | US | Manufacturing |
|
ANIMALCARE GROUP PLC
Develops and commercializes veterinary pharmaceutical produ…
|
ANCR | GB | Manufacturing |
|
ANI PHARMACEUTICALS INC
Develops, manufactures, and markets branded, generic, and O…
|
ANIP | US | Manufacturing |
|
ANLON HEALTHCARE LIMITED
Researches and manufactures APIs, intermediates, and finish…
|
AHCL | IN | Manufacturing |
|
Annexin Pharmaceuticals AB
Clinical-stage biotech developing a cell-protecting biologi…
|
ANNX | SE | Manufacturing |
|
Annexon, Inc.
Clinical-stage biopharma developing complement medicines by…
|
ANNX | US | Manufacturing |
|
Antengene Corporation Limited
Global biopharma developing and commercializing novel oncol…
|
6996 | KY | Manufacturing |
Nuvalent, Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/30903/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=30903 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=30903 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=30903 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 30903}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Nuvalent, Inc. (id: 30903)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.